Cellectis S.A. (CLLS) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed Humacyte (HUMA) over the past year, losing 70.9% versus a loss of 73.5%. Over five years, CLLS leads with a -88.5% price change compared with -95.6% for HUMA. Cellectis S.A. is the larger company by market cap ($126.4 million vs $110.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | HUMA |
|---|---|---|
| Share price | $1.26 | $0.3993 |
| Market cap | $126.42M | $110.92M |
| 1-day change | +0.40% | -10.69% |
| YTD return | -74.17% | -53.48% |
| 1-year return | -70.93% | -73.54% |
| 5-year return | -88.46% | -95.63% |
| EPS (TTM) | $-0.64 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $1.90 |
| 52-week low | $1.22 | $0.391 |
| Distance from 52-week high | -77.10% | -78.93% |
| Analyst consensus | none | buy |
| Avg. price target upside | +324.70% | +308.21% |
| Average volume | 80.14K | 6.23M |
| Shares outstanding | 72.73M | 277.80M |
| Employees | 224 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
CLLS vs HUMA FAQ
Which is bigger, Cellectis S.A. or Humacyte?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $126.42M compared with $110.92M for Humacyte (HUMA).
Which stock has performed better over the past year, CLLS or HUMA?
CLLS returned -70.93% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Humacyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cellectis S.A. and Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte.